Search

Displaying results 3391 - 3400 of 10000 in total
  1. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  2. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    It has also been studied in atherosclerosis and acute renal failure [A32001]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456]. … Initially, it was marketed in 1995 under the trade name, _Landel_. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001].

  3. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

  4. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.

  5. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]

  7. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

  8. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  9. Drug

    Factor IX Complex (Human)

    go.drugbank.com/drugs/DB11330
    ApprovedInvestigational

    Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. … As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients

    Synonyms: Coagulation factor IX, II, VII and X in combinationProducts: BERIPLEX P/N 250 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, BERIPLEX P/N 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET
  10. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting...